- Home
- PLRZ vs OGEN Comparison
PLRZ vs OGEN Comparison
Compare PLRZ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRZ
- OGEN
- Stock Information
- Founded
- PLRZ 2005
- OGEN 1996
- Country
- PLRZ Israel
- OGEN United States
- Employees
- PLRZ N/A
- OGEN N/A
- Industry
- PLRZ
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- PLRZ
- OGEN Health Care
- Exchange
- PLRZ NYSE
- OGEN Nasdaq
- Market Cap
- PLRZ 5.9M
- OGEN 5.5M
- IPO Year
- PLRZ 2024
- OGEN N/A
- Fundamental
- Price
- PLRZ $1.54
- OGEN $0.28
- Analyst Decision
- PLRZ
- OGEN
- Analyst Count
- PLRZ 0
- OGEN 0
- Target Price
- PLRZ N/A
- OGEN N/A
- AVG Volume (30 Days)
- PLRZ 8.2M
- OGEN 1.7M
- Earning Date
- PLRZ 02-15-2025
- OGEN 11-13-2024
- Dividend Yield
- PLRZ N/A
- OGEN N/A
- EPS Growth
- PLRZ N/A
- OGEN N/A
- EPS
- PLRZ N/A
- OGEN N/A
- Revenue
- PLRZ N/A
- OGEN N/A
- Revenue This Year
- PLRZ N/A
- OGEN N/A
- Revenue Next Year
- PLRZ N/A
- OGEN N/A
- P/E Ratio
- PLRZ N/A
- OGEN N/A
- Revenue Growth
- PLRZ N/A
- OGEN N/A
- 52 Week Low
- PLRZ $0.77
- OGEN $0.25
- 52 Week High
- PLRZ $4.80
- OGEN $6.22
- Technical
- Relative Strength Index (RSI)
- PLRZ N/A
- OGEN 38.94
- Support Level
- PLRZ N/A
- OGEN $0.34
- Resistance Level
- PLRZ N/A
- OGEN $0.42
- Average True Range (ATR)
- PLRZ 0.00
- OGEN 0.05
- MACD
- PLRZ 0.00
- OGEN -0.01
- Stochastic Oscillator
- PLRZ 0.00
- OGEN 5.05
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.